anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject drink easily drinkable with a simple treatment without giving disagreeable feeling by adding a functional food raw material in the preparation of a drink and attaching the food raw material to the surface of the drink simultaneous to the processing. CONSTITUTION:A food raw material such as edible fiber, oligosaccharide, calcium, taurine. iron, etc., is added in the form of fine powder or an aqueous solution to a drink generally taken as a luxury drink such as tea, coffee or cocoa. The functional food raw material is attached to the surface of the drink simultaneous to processing to obtain the objective drink containing functional food raw material. The functional food raw material can be added to the drink by this process without losing the properties and natures of the drink used as a base. Accordingly, the health-promoting effect of the functional food raw material can be ntilized while enjoying the characteristic color, fragrance and taste of the drink.
This application is directed to a centralized power data management system for managing power data of remote medical devices located at one or more medical facilities. A server is communicatively coupled to a plurality of power cables. Each power cable includes a cord device and is electrically coupled to, and configured to power, a respective medical device. A power profile is received from a first cord device of a first power cable and includes power data characteristics measuring power delivered to a first medical device while the first medical device conducts a medical procedure. The power profile is used to identify the conducted medical procedure, including one or more numeric operational parameters of the medical procedure. The computer system sends a message associated with the conducted medical procedure to a second electronic device for display on a user interface of the second electronic device.
Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
Patients will be recruited on the day they are going to start the egg donation program. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion and will call the site to initiate the oocyte donation protocol approximately 30 days after enrollment. Throughout the COH period of the protocol the patient will continue taking the study supplement (or placebo), without interruption until the day of the GnRH-agonist trigger. The administration of the agonist will be as a single dose, 36 hours before follicular puncture for the retrieval of mature eggs. Then, the retrieved oocytes will be denuded and examined by light microscopy to assess their quality. The evaluation will carried out by two different embryologists, blinded to the study protocol.
The present invention provides a medicine compound including the following raw materials with the weight portions such as 18 to 30 portions of prepared rehmannia rhizome, 9 to 12 portions of cornus dogwood fruit, 8 to 16 portions of Chinese yam, 9 to 12 portions of medlar, 8 to 16 portions of field dodder and 8 to 16 portions of deerhorn glue, and the purpose in preparing the medicine for delaying vaginal aging. The medicine is an active medicine for strengthening external gonad tissue aromatase and a medicine for increasing vaginal blood supply. The medicine is a medicine for preventing or/and curing senile vaginitis. Under a specific diagnosis standard, the medicine provided by the present invention has definite efficacy. The medicine has the advantages of same efficacy on delaying vaginal aging, few raw materials, wide sources, effective cost saving due to selection of raw materials, no effect on the level of serum estrogen after long-term administration, no proliferation on endometrium and safety. The present invention provides a new choice for clinically curing senile vaginitis, in particular preventing senile vaginitis or recurrence of senile vaginitis.
Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.

“Drug seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may be accompanied by concurrent tolerance and symptoms of physical dependence. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since fentanyl transdermal system may be diverted for non-medical use, careful recordkeeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.
The TranS-C group will receive weekly 2 hour TranS-C group intervention delivered by 2 clinical psychology trainees for 6 weeks, contents being core modules from Harvey et al. (2016)'s protocol.
The invention discloses an amphiphilic curcumin prodrug micelle and a preparation method thereof, and belongs to the field of biomedical high polymer materials. According to the invention, quaternary ammonium salt hydroxyethyl starch is used as a polymer framework, ethylene dithio-diacetic acid is used as a connecting arm, and hydrophobic curcumin and quaternary ammonium salt hydroxyethyl starch are coupled to obtain the curcumin prodrug capable of self-assembling to form a stable micelle structure. The curcumin prodrug can be prepared through two-step esterification reaction, and the preparation process is simple. The obtained curcumin prodrug can self-assemble in aqueous solution to form nano micelle, and can improve solubility and stability of curcumin in water. Curcumin can be released in a responsive way under the active oxygen and weak acid environment, so that the release and accumulation of curcumin at tumor sites are enhanced. The prodrug can effectively inhibit proliferation of colon cancer cells, and can provide reference for clinical application of curcumin.
Compositions for a foaming oral cleaner and related methods and products are disclosed. In one such method, a foaming oral cleaner may be dispensed onto a cleaning surface of a tongue cleaning device in a manner to foam the foaming oral cleaner. A surface of the tongue may be brushed using a tongue brush of the tongue cleaning device, thereby applying the foaming oral cleaner to the surface of the tongue. The brushing of the surface of the tongue can dislodge and loosen material on the surface of the tongue. The surface of the tongue can be scraped using a tongue scraper of the tongue cleaning device to scrape dislodged and loosened material from the surface of the tongue. The foaming oral cleaner may be a composition comprising water, a foaming agent, a sweetener, a flavoring agent, an antimicrobial agent comprising a biologically active enzyme, a preservative, and a coloring agent.
Mother-to-child transmission (MTCT) of HIV can be caused either by perinatal transmission of HIV or by breastfeeding, a common practice in poorer regions of the world. HIV preventive vaccines are currently under investigation as potential solutions to worldwide MTCT of HIV. This study will evaluate the safety and immunogenicity of an HIV-1 vaccine, ALVAC-HIV vCP1521, in infants born to HIV-1 infected mothers in Uganda. The vaccine is a preparation of a live attenuated recombinant canarypox virus, encoding HIV clades B and E envelope proteins. This study will be conducted at Mulago Hospital in Uganda.

Mothers will enroll in this study during their third trimesters of pregnancy. During screening, mothers will undergo medical history assessment, a physical exam, and blood collection. After delivery and prior to infant enrollment, mothers will have another physical exam; mothers and their infants will be accompanied home by a home visitor who will document contact information.

Infants will be followed for 24 months after birth. Infants will be randomly assigned to receive 4 injections of vaccine or placebo. Study injections will be given at the start of the study and at Weeks 4, 8, and 12. Infants will be observed for 1 hour after each vaccine administration to check for body temperature and local and systemic reactions. They will also be evaluated in the clinic the day after each immunization for any local or systemic reactions. Infants will be visited at home 2 days after vaccine administration by a trained study nurse who will assess reactogenicity. Blood will be collected at 9 selected times: study entry, Weeks 2, 6, 10, and 14, and Months 6, 12, 18, and 24. Sixteen study visits occurring over 2 years will include medical history assessment and physical exams. Childhood immunizations will be given to infants at study entry and at Weeks 6, 10, and 14 and Months 6 and 12.
A contrast medium for diagnosing cancer diseases is provided to enable imaging from MRI (magnetic resonance imaging) to gamma imaging by injecting one contrast medium. A contrast medium of the chemical formula 1 for diagnosing cancer diseases using MRI (magnetic resonance imaging) comprises targets a superpra iron oxide nano particle, linker and ligand targeting parenchymal cell. In the chemical formula 1, SPIO is superpra iron oxide nano particle. The nano particle size is 4-200nm. The linker is dopamine. The ligand is lactobionic acid containing beta-glucose. A method for manufacturing the contrast medium comprises: a step of synthesizing and growing iron oxide nano particle; a step of reforming the iron oxide nano particle with linker; and a step of reforming the parenchymal cell with ligand.
PROBLEM TO BE SOLVED: To obtain tablets which are compressed and chewable and improved in taste, exhibiting such low crushability as to treat it with standard bulk treating equipment and enable bottling by including an active component, a carbohydrate and a binder and specifying the shape and hardness. SOLUTION: The tablets comprises (A) an active ingredient, (B) water- disintegrable and compressible carbohydrate and (C) a binder and is provided with the opposed front sides which have protruded shape and have about 2-11 kp/cm2, preferably 5-8.5 kp/cm2 hardness. The tablets are prepared by drying and mixing, e.g. these components A to C and compressing the mixture into protruded tablets having about 2-11 kp/cm2. The tablets are preferably covered with taste-masking composition when the active ingredient has unpleasant taste. The tablets are improved in taste and palatability because of being softer than conventional chewable tablets.
A therapeutic product in the form of a powder or injection comprises an oxytetracycline antibiotic and magnesium chloride, preferably in anhydrous form and in proportions of 0.5 to 3 mols. per mol. of the oxytetracycline antibiotic.  The oxytetracycline antibiotic is any therapeutic form of oxytetracycline, e.g. amphoteric oxytetracycline and salts such as the hydrochloride and sulphate.  For injections the solids are preferably finely divided (i.e. less than 100 microns) and dissolved or suspended in an injectable vehicle such as water, propylene glycol or a vegatable oil such as sesame oil or peanut oil. Optional ingredients are local an sthetics such as procaine hydrochloride.  Aqueous solutions are unstable and should be prepared within one hour of use.  Specification 714,085 is referred to.
The sponsor will first analyze menstrual blood (MB) samples in three discreet studies: breast, endometrial, lung. According to American Institute for Cancer Research, "Endometrial cancer is the most common cancer of the female reproductive organs. More cases of endometrial cancer occur each year than ovarian and cervical cancers combined." 20% to 25% will be diagnosed with endometrial cancer before menopause. Based on the patient recruitment potential and high impact on women's health, these three cancer types are suitable models to evaluate the expediency of utilizing MB as an ideal source for identification of cancer markers.

Health profiles are completed by all participants and where applicable and possible, patient medical records, health tracking device data, etc. will be included. Blood samples will be collected as indicated on the collection protocol outlined by LifeStory Health's (LSH's) Protocol and Instructions for Use. Samples will be collected in the participant's home according to LSH's Collection Protocol using EBF-Inc.'s 903 dried blood spot (DBS) collection device prior shipment to the research center. Samples should be sent within 3 days of collection. Up to one-hundred and fifty micro-liters (150 uL) of menstrual blood can be collected from donors using the collection device.Samples will be processed according to LSH's protocol and any methods outlined in this development plan.

The study will receive samples from 60 female participants, totaling 30 samples from early-stage cancer patients and 30 samples from healthy women. After initial determination of potential cancer markers for all three cancer types, the sponsor will select a single cancer type with the most promising results ("Cancer 1") and carry out additional, statistically higher-powered, studies on all four stages of this selected cancer. After the identities of potential MB biomarkers for a single cancer type are re-confirmed and established at the highest level of confidence, simple assays will be developed for cost-effective detection of target proteoforms for early detection of cancer.

Overall conduct of the study is the responsibility of the recruiting facilities/physicians. LifeStory Health provides operational oversight. The Baylor Scott and White Research Division (BSW) is responsible for oversight of the Regional Centers. LifeStory Health is responsible for data collection,management and analysis. Study patient safety and study performance are monitored by BSW. This study is being conducted with LifeStory Health and principal investigator, Anna Villarreal, CEO and Founder of LifeStory Health Inc.This randomized, double blind, controlled trial will enroll 60 patients.
BACKGROUND AND OBJECTIVES: Idiopathic hypersomnia (IH) is a CNS disorder of hypersomnolence of unknown etiology. Due to the requirement for objective sleep testing to diagnose the disorder, there are currently no population-based estimates of the prevalence of IH nor data regarding the longitudinal course of IH in naturalistic settings.
METHODS: Subjective and objective data from the Wisconsin Sleep Cohort study were used to identify cases with probable IH from participants with polysomnography and multiple sleep latency test data. Demographic, polysomnographic, and symptom-level data were compared between those with and without IH. Longitudinal trajectories of daytime sleepiness among those with IH were assessed to evaluate symptom persistence or remission over time.
RESULTS: From 792 cohort study participants with available polysomnography and multiple sleep latency test data, 12 cases with probable IH were identified resulting in an estimated prevalence of IH of 1.5% (95% CI 0.7-2.5, p < 0.0001). Consistent with inclusion/exclusion criteria, cases with IH had more severe sleepiness and sleep propensity, despite similar or longer sleep times. Longitudinal data (spanning 12.1 ± 4.3 years) demonstrated a chronic course of sleepiness for most of the cases with IH, though pathologic somnolence remitted in roughly 40% of cases.
DISCUSSION: These results demonstrate IH is more common in the working population than generally assumed with a prevalence on par with other common neurologic and psychiatric conditions. Further efforts to identify and diagnose those impaired by unexplained daytime somnolence may help clarify the causes of IH and the mechanisms underlying symptomatic remission.
BACKGROUND: This study aimed to compare the diagnostic yield of the FRAIL scale with respect to the physical frailty phenotype measure and their association with mortality in non-dialysis-dependent patients.
METHODS: In this prospective cohort study, non-dialysis dependent patients with chronic kidney disease (CKD) stages 3b-5 seen in the nephrology outpatient clinics of two university hospitals were included. The presence of frailty was evaluated by physical frailty phenotype measure and the FRAIL scale. Patients were evaluated for six months, and mortality was recorded. The Kappa test was used to evaluate the diagnostic properties between the methods, and logistic regression to test the association between frailty and mortality.
RESULTS: One hundred fifty-three patients were evaluated; average age was 65 (56-70) years, 50.9% were women, and the all-cause mortality rate was 2.6%. Forty-six patients were classified as living with frailty according to the physical frailty phenotype while 36 patients were rated frail by the FRAIL scale. In adults < 60 years of age, the FRAIL scale showed good accuracy (84.9%) and specificity (93.2%) but had low sensitivity (41.3%) and moderate agreement (Kappa = 0.41; p < 0.001) compared to the definition of the physical frailty phenotype. The adjusted logistic regression model showed that the patients with frailty assessed by the FRAIL scale had a greater chance of mortality than the non-frail patients (OR: 6.8; CI95%:1.477-31.513; p = 0.014).
CONCLUSION: Physical frailty phenotype identifies more patients as having pre-frailty and frailty in non-dialysis dependent patients as compared to the FRAIL scale. However, the FRAIL scale is a simple bedside tool that can be useful for screening for frailty and whose results were associated with mortality.
The 1st physical therapist performed the modified Thomas test position. The participant was asked to lie supine over the edge of the couch. The participant hold one knee to the chest tightly while the other knee was bent over the end of the couch. The 2nd physical therapist measured angles of hip and knee using a standard goniometer at baseline. The quadratus lumborum muscle was released. Then the same measurement was repeated.
Recent evidence shows that pre-diabetes is characterized by marked alterations in 24h substrate metabolism, indicating metabolic inflexibility with an inability to fully switch to fat oxidation during the night. Whereas exercise has been shown to promote mitochondrial function and insulin sensitivity, it is unknown to if exercise training is able to restore 24h rhythmicity in overall substrate metabolism and muscle metabolism in human subjects with pre-diabetes.

In this single-arm longitudinal design, subjects will serve as their own control. Subjects will perform high-intensity interval training for 12 weeks (3x times per week) on a cycle ergometer at the research facility. Pre and post exercise, subjects will stay in a metabolic chamber and adhere to a relatively normal life-style in order to standardize the main 24h measurement period. As the primary outcome, substrate metabolism will be measured with a ventilated hood system and by indirect calorimetry in the chambers. Muscle biopsies from the vastus lateralis and frequent blood samples will also be taken over the course of the 24h. Thereby, ex-vivo skeletal muscle mitochondrial function and muscle clock gene expression will serve as the main secondary outcomes.
FIELD: medicine, microbiology. SUBSTANCE: method deals with determining the titer of specific antibodies in case of acute and chronic glanders in indirect- hemagglutination test. The method deals with applying microbes of B.mallei C-5 strain as an industrial one, isolating a specific antigenic complex with 1-% cetavlone solution, modification of erythrocytic surface with 0.005-% tannin solution. Sensitization is conducted at pH 7.0-7.2 by mixing the solution of antigenic complex and erythrocytic suspension at the rate of 100 mcg/ml 2.5-% suspension at 2-6 C with subsequent incubation for 18-20 h. The method provides to obtain a high-sensitive, specific and stable erythrocytic diagnostic kit. EFFECT: higher accuracy of diagnostics. 5 tbl
PURPOSE: To evaluate the predictive capabilities of MRI-based radiomics for detecting lymphovascular space invasion (LVSI) in patients diagnosed with endometrial carcinoma (EC).
MATERIALS AND METHODS: A retrospective analysis was conducted on 160 female patients diagnosed with EC. The radiomics model including T2-weighted and dynamic contrast-enhanced MRI (DCE-MRI) images was established. Additionally, a conventional MRI model, which incorporated MRI-reported FIGO stage, deep myometrial infiltration (DMI), adnexal involvement, and vaginal/parametrial involvement, was established. Finally, a combined model was created by integrating the radiomics signature and conventional MRI characteristics. The predictive performance was validated by the area under the curve (AUC) of the receiver operating characteristic (ROC) curves. A stratified analysis was conducted to compare the differences between the three models by Delong test.
RESULTS: In predicting LVSI, the radiomics model outperformed the clinical model in the training cohort (AUC: 0.899 vs. 0.8862) but not in the test cohort (AUC: 0.812 vs. 0.8758). The combined model demonstrated superior performance in both the training and test cohorts (training cohort: AUC = 0.934, 95% CI: 0.8807-0.9873; testing cohort: AUC = 0.905, 95% CI: 0.7679-1).
CONCLUSIONS: The combined model exhibited utility in preoperatively predicting LVSI in patients with EC, offering potential benefits for clinical decision-making.